LARIMAR THERAPEUTICS INC (LRMR) Stock Income Statement
NASDAQ:LRMR - Nasdaq - US5171251003 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 90.89M | 41.76M | 36.53M | 50.47M | 42.80M | |||
| Research and Development | 73.28M | 27.67M | 24.25M | 38.40M | 31.41M | |||
| Selling, General, and Administrative Expenses | 17.61M | 14.09M | 12.28M | 12.07M | 11.40M | |||
| Operating Income | -90.89M | -41.76M | -36.53M | -50.47M | -42.80M | |||
| Interest Income/Expense | N/A | N/A | N/A | N/A | N/A | |||
| Other Income/Expense | 10.29M | 4.81M | 1.17M | -171.00K | 322.00K | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | -80.60M | -36.95M | -35.35M | -50.64M | -42.48M | |||
| Income Tax | 0.00 | N/A | N/A | N/A | N/A | |||
| Net Income | -80.60M | -36.95M | -35.35M | -50.64M | -42.48M | |||
| EBITDA | -90.57M | -41.45M | -36.21M | -50.14M | -42.65M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.32 | -0.84 | -1.37 | -2.95 | -3.57 | |||
| Non GAAP EPS | -1.30 | -0.85 | -1.54 | -2.97 | -3.94 | |||
| Statistics | ||||||||
All data in USD